Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Amgen and Genentech have been synonymous with biotech. They long held the first two spots among biotechs based on market cap. In 2009, Roche, which already held 55.8% of Genentech, shelled out $46.8 billion to take over the rest of this biotech giant. That acquisition helped move Roche up to the number two spot among pharmas, but that meant Genentech was no longer second among biotechs. You can check out a list of the top 30 biotech companies by market cap by clicking here for intriguing biotech facts compiled for our 30th anniversary issue. Which of the current top three players do you think is being eyed by those in the pharma world?